Our Technologies


Our stem cell expansion and screening technologies have enabled us to generate quality-assured stem cell lines in quantities sufficient to treat many hundreds of thousands of potential patients. Read More ....


Subscribe here for our Press Releases

Our Products


We have developed stem cell therapies for serious conditions such as stroke disability where the patient populations are significant and where few if any alternative treatments exist. Read More ....

Share Price

To view detailed share price information
for ReNeuron Group plc. Click Here

Latest News

ReNeuron Group plc (AIM: RENE), a leading UK-based stem cell therapy company, will announce its interim results for the six months ended 30 September 2014 on Monday 17 November 2014. More
After fund manager Neil Woodford bought a 20% stake in ReNeuron, CFO Michael Hunt discusses the opportunities for the
Michael Hunt CFO of ReNeuron gives an interview at Edison to discuss company prospects More

ReNeuron is a leading, clinical-stage stem cell business. Our primary objective is the development of novel stem cell therapies targeting areas of significant unmet or poorly met medical need. Read more ....

©ReNeuron Group plc 2005-2014 All rights reserved

Privacy                Disclaimer